Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07104539 · ClinicalTrials.gov registry record · NA

Strength Training Response of Muscle in GLP-1 Users

A NA study of Muscle Mass, sponsored by Virginia Polytechnic Institute and State University.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT07104539 is a NA study of Muscle Mass that is actively recruiting participants, run by Virginia Polytechnic Institute and State University. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07104539, a NA study of Muscle Mass, is actively recruiting participants, sponsored by Virginia Polytechnic Institute and State University.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.

Conditions Studied

Interventions

  • BEHAVIORAL Strength Training
  • OTHER Wait first, then strength training

Study Locations (1)

Virginia

  • Virginia Tech - Blacksburg

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-10-08
Est. Completion 2027-05
Phase NA

What the Registry Record Tells You About NCT07104539

The ClinicalTrials.gov registry entry for NCT07104539 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Polytechnic Institute and State University, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Muscle Mass appearing as the primary indexed condition, and to 2 interventions - of which Strength Training is the first listed.

NCT07104539 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.

Frequently Asked Questions

What is clinical trial NCT07104539 about?

NCT07104539 is a clinical study titled "Strength Training Response of Muscle in GLP-1 Users". GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults a...

What is the current status of trial NCT07104539?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-10-08. Estimated completion is 2027-05.

What conditions does trial NCT07104539 study?

This clinical trial studies the following conditions: Muscle Mass.

What interventions are being tested in trial NCT07104539?

The interventions under investigation include: Strength Training (BEHAVIORAL), Wait first, then strength training (OTHER).

Who is sponsoring clinical trial NCT07104539?

This trial is sponsored by Virginia Polytechnic Institute and State University, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07104539 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Muscle Mass

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.